Clinical Trials
Sarcoma Cancers
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
- Disease/Condition: Soft Tissue
- Principal Investigator: Hari Deshpande
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
- Disease/Condition: Bones and Joints | Brain and Nervous System | Leukemia, not otherwise specified | Leukemia, other | Lymphoid Leukemia
- Principal Investigator: Nina Kadan-Lottick
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- Disease/Condition: Soft Tissue
- Principal Investigator: Hari Deshpande
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
- Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
- Principal Investigator: Patricia LoRusso
A Phase I/ Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
- Disease/Condition: Soft Tissue
- Principal Investigator: Hari Deshpande
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
- Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
- Principal Investigator: Patricia LoRusso
A Phase I Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
- Disease/Condition: Anus | Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Leukemia, other | Lip, Oral Cavity and Pharynx | Liver | Lung | Lymphoid Leukemia | Melanoma, skin | Multiple Myeloma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Other Hematopoietic | Unknown Sites
- Principal Investigator: Thomas Prebet
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Disease/Condition: Bones and Joints | Brain and Nervous System | Eye and Orbit | Hodgkin's Lymphoma | Kidney | Leukemia, other | Liver | Lymphoid Leukemia | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Small Intestine | Soft Tissue | Pediatrics
- Principal Investigator: Nina Kadan-Lottick
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Disease/Condition: Soft Tissue | Pediatrics
- Principal Investigator: Nina Kadan-Lottick
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
- Disease/Condition: Bones and Joints | Pediatrics
- Principal Investigator: Nina Kadan-Lottick
